December 16, 2024 11:23 AM EST
Pharma
FDA+

Check­point wins FDA ap­proval of check­point in­hibitor in ad­vanced skin can­cer, seeks part­ner for launch

Lei Lei Wu

News Reporter

The FDA ap­proved Check­point Ther­a­peu­tics’ an­ti-PD-L1 an­ti­body cosi­be­limab in a form of ad­vanced skin can­cer, the com­pa­ny an­nounced Fri­day.

The im­mune …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Bi­cy­cle Ther­a­peu­tics stock sinks fol­low­ing re­lease of topline da­ta, post-hoc analy­ses

Roche ter­mi­nates a Phase 3 Spark gene ther­a­py in he­mo­phil­ia A

Bris­tol My­ers drops cell ther­a­py pacts with Im­mat­ics, Cen­tu­ry as part of port­fo­lio re­view

Neu­ro­crine gets FDA go-ahead to treat rare adren­al gland con­di­tion

Virid­i­an read­ies for Te­pez­za ri­val­ry with new Phase 3 da­ta in thy­roid eye dis­ease

A service from the Financial Times